STAT+: Social media diss highlights high-stakes rivalry over colon cancer blood tests
Biotech companies routinely compete to develop and commercialize products. But these rivalries are seldom as…
Category: biotechnology
Bernie Sanders keeps the heat on Novo’s high prices
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion
Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of…
FDA formalizes protocol for international cancer trials
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The news from ESMO: An immunotherapy milestone, studying young-onset cancers, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
The essential biotech updates of the day
Morning! Today, we talk about bioethics, catch up on some reports from ESMO, and wonder aloud…
STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present
For decades, the biotech company Genentech has carved out a reputation in the industry as…
STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending
Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced…
STAT+: Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
BARCELONA, Spain — Patients with advanced cancers often develop a secondary condition that causes them…
STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK…
Can GLP-1 drugs help with type 1 diabetes?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in…
STAT+: Can iTeos and GSK solve TIGIT’s troubles?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
Moderna cuts spending, and Sarepta’s ‘curse’ on Califf
Good morning. If you’re following the European Society for Medical Oncology meeting that starts tomorrow,…
STAT+: Gilead’s twice-yearly antiviral protects against HIV infection in second large trial
Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96%…
Opinion: STAT+: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma
In a rare display of bipartisan agreement, Congress is getting serious about addressing China’s influence…
Eli Lilly releases new data on weekly insulin
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory…
STAT+: Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone…
Five biotech news stories you need to read today
Morning! Today, we’ll keep riding the bispecific wave, and tell you what Verily and FDA…
STAT+: Viridian drug achieves study goals as treatment for thyroid eye disease
Viridian Therapeutics said Tuesday that an experimental treatment improved the signs and symptoms of thyroid…
STAT+: Roivant acquires drug for pulmonary hypertension from Bayer
For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the…
STAT+: House passes bill that targets China biotechs
WASHINGTON — The House Monday passed a bill by 306 to 81 votes to make…
Terns’ GLP-1 pill leads to weight loss in early study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Merck executive plays down impact of new lung cancer drug data on Keytruda
With strong data released over the weekend, an experimental Chinese drug showed it could one…
STAT+: Relay discloses encouraging results for experimental breast cancer treatment
Relay Therapeutics disclosed encouraging results for its key breast cancer drug and plans to advance…
STAT+: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its…
STAT+: Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial
SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens…
STAT+: Vor Biopharma’s ‘shielded’ transplant delays relapse in leukemia patients
A CRISPR-augmented stem cell transplant that protects healthy cells from the toxic effects of anti-cancer…
Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target
How effective is Summit Therapeutics’ lung cancer immunotherapy? Why are obesity drugmakers turning back to…
STAT+: U.K. charities give $36 million to start new drugs for childhood tumors
For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and…
Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after Covid delays
Federal regulators responsible for the safety of the U.S. drug supply are still struggling to…
Lilly has more positive data on its weekly insulin
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal
Let’s set the table for Sunday’s presentation of the lung cancer immunotherapy trial known as…
STAT+: Alnylam versus BridgeBio: The ATTR-CM debate
I coined the term “Typo-gate” to describe the misguided dustup Alnylam Pharmaceuticals executives instigated last…
BioMarin’s big day today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance
Novartis is opening a new manufacturing facility in California and expanding an existing production site…
STAT+: European court sides with Illumina, saying regulators overstepped in scrutiny of Grail deal
LONDON — Europe’s top court on Tuesday ruled that regulators overstepped in challenging the DNA…
STAT+: Diagnosed with cancer, a pharmaceutical executive became a patient advocate and changed drug development. It took decades
Kathy Giusti was diagnosed with multiple myeloma in 1996, when she was a 37-year-old executive…
STAT+: Detailed data on Alnylam’s heart drug show substantial benefit, while competition likely awaits
LONDON — An experimental drug from Alnylam Pharmaceuticals substantially cut the risk of death and…
STAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows
LONDON — Novo Nordisk made worldwide headlines last year when a study demonstrated that Wegovy,…
STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a…
Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy
What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213…
STAT+: Thoughts, takes, and burning biotech questions as the beginning of the end of the year approaches
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
Genentech is shedding even more employees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?
Hims & Hers, one of the largest publicly traded telehealth companies in the country, has…
Hims takes a blow from Lilly’s vial news
Good morning. As a treat for Labor Day weekend, we’re running a deal for STAT+…
STAT+: Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial
Neurocrine Biosciences said Wednesday that the lowest dose of an experimental pill for schizophrenia reduced…
Pfizer and Lilly want to sell you drugs directly
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Lilly launches Zepbound vials in move that could ease supply constraints
Eli Lilly said Tuesday that it will start providing low-dose vials of its obesity drug…